• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HYD-PEP06通过抑制PI3K/AKT和WNT/β-连环蛋白信号激活来抑制肝细胞癌转移、上皮-间质转化及癌症干细胞样特性。

HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/-catenin signaling activation.

作者信息

Tian Wei, Li Jiatong, Wang Zhuo, Zhang Tong, Han Ying, Liu Yanyan, Chu Wenfeng, Liu Yu, Yang Baofeng

机构信息

Department of Pharmacology (the State-Province Key Laboratories of Biomedicine Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China.

The First Affiliated Hospital of Harbin Medical University, Harbin 150081, China.

出版信息

Acta Pharm Sin B. 2021 Jun;11(6):1592-1606. doi: 10.1016/j.apsb.2021.03.040. Epub 2021 Apr 2.

DOI:10.1016/j.apsb.2021.03.040
PMID:34221870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8245914/
Abstract

HYD-PEP06, an endostatin-modified polypeptide, has been shown to produce effective anti-colorectal carcinoma effects through inhibiting epithelial-mesenchymal transition (EMT). However, whether HYD-PEP06 has similar suppressive effect on hepatocellular carcinoma (HCC) remained unknown. In this study, HYD-PEP06 inhibited metastasis and EMT but not proliferation . Cignal finder pathway reporter array and Western blot analysis revealed that HYD-PEP06 suppressed HCCLM3 cell metastasis and EMT by inhibiting the PI3K/AKT pathway. Moreover, HYD-PEP06 exerted anti-metastasis effects in HepG2 cancer stem-like cells (CSCs) suppressing the WNT/-catenin signaling pathway. Finally, in HCCLM3 tumor-bearing BALB/c / nude mice, HYD-PEP06 substantially suppressed tumor growth, lung metastasis and HCC progress. Our results suggest that HYD-PEP06 inhibits the metastasis and EMT of HCC and CSCs as well, and thus has the potential as an agent for HCC treatment.

摘要

HYD-PEP06是一种内皮抑素修饰的多肽，已被证明可通过抑制上皮-间质转化（EMT）产生有效的抗结直肠癌作用。然而，HYD-PEP06对肝细胞癌（HCC）是否具有类似的抑制作用尚不清楚。在本研究中，HYD-PEP06抑制转移和EMT，但不抑制增殖。信号发现者通路报告基因阵列和蛋白质印迹分析表明，HYD-PEP06通过抑制PI3K/AKT通路抑制HCCLM3细胞转移和EMT。此外，HYD-PEP06在肝癌干细胞样细胞（CSCs）中发挥抗转移作用，抑制WNT/β-连环蛋白信号通路。最后，在荷HCCLM3肿瘤的BALB/c裸鼠中，HYD-PEP06显著抑制肿瘤生长、肺转移和HCC进展。我们的结果表明，HYD-PEP06也抑制HCC和CSCs的转移和EMT，因此有潜力作为一种HCC治疗药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/d41e80b08693/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/1462fe332250/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/7a28f43ec52f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/498a1b78430c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/c36b922f55f1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/b2ef9188dd62/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/3401676ecccc/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/36e3bea87d2b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/01abc9d4374e/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/558cdfbe3836/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/a484542310bc/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/d41e80b08693/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/1462fe332250/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/7a28f43ec52f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/498a1b78430c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/c36b922f55f1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/b2ef9188dd62/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/3401676ecccc/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/36e3bea87d2b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/01abc9d4374e/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/558cdfbe3836/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/a484542310bc/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d54c/8245914/d41e80b08693/gr10.jpg

相似文献

1
HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/-catenin signaling activation.HYD-PEP06通过抑制PI3K/AKT和WNT/β-连环蛋白信号激活来抑制肝细胞癌转移、上皮-间质转化及癌症干细胞样特性。
Acta Pharm Sin B. 2021 Jun;11(6):1592-1606. doi: 10.1016/j.apsb.2021.03.040. Epub 2021 Apr 2.
2
PEP06 polypeptide 30 exerts antitumour effect in colorectal carcinoma via inhibiting epithelial-mesenchymal transition.PEP06 多肽 30 通过抑制上皮-间充质转化发挥抗肿瘤作用在结直肠癌中。
Br J Pharmacol. 2018 Aug;175(15):3111-3130. doi: 10.1111/bph.14352. Epub 2018 Jun 15.
3
DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways.DUXAP10 抑制通过调节 Wnt/β-catenin 和 PI3K/Akt 信号通路抑制肝癌细胞的增殖和转移。
Biosci Rep. 2019 May 31;39(5). doi: 10.1042/BSR20181457.
4
Essential Oil Inhibits Hepatocellular Carcinoma Metastasis via Suppression of DEPDC1 Dependent Wnt/β-Catenin Signaling Pathway.精油通过抑制DEPDC1依赖的Wnt/β-连环蛋白信号通路抑制肝细胞癌转移。
Front Cell Dev Biol. 2021 Jun 29;9:664791. doi: 10.3389/fcell.2021.664791. eCollection 2021.
5
PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting v integrin/FAK/Src signaling in oral squamous cell carcinoma cells.PEP06多肽30是一种新型的簇解离剂，可抑制口腔鳞状细胞癌细胞中的v整合素/黏着斑激酶/ Src信号通路。
Acta Pharm Sin B. 2019 Nov;9(6):1163-1173. doi: 10.1016/j.apsb.2019.10.005. Epub 2019 Oct 18.
6
Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway.苦参碱通过抑制Wnt-1/β-连环蛋白信号通路改善肝细胞癌的肝微环境并逆转上皮-间质转化。
Am J Transl Res. 2023 Aug 15;15(8):5047-5070. eCollection 2023.
7
UNC119 promotes the growth and migration of hepatocellular carcinoma via Wnt/β/catenin and TGF/β-EMT signaling pathways.UNC119通过Wnt/β/连环蛋白和TGF/β-上皮-间质转化信号通路促进肝细胞癌的生长和迁移。
J BUON. 2018 Jan-Feb;23(1):188-192.
8
NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma.NTS/NTR1共表达通过激活肝细胞癌中的Wnt/β-连环蛋白信号通路增强上皮-间质转化并促进肿瘤转移。
Oncotarget. 2016 Oct 25;7(43):70303-70322. doi: 10.18632/oncotarget.11854.
9
MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.微小 RNA-1296 通过靶向 SRPK1 介导的 PI3K/AKT 通路抑制肝癌的转移和上皮-间充质转化。
Mol Cancer. 2017 Jun 12;16(1):103. doi: 10.1186/s12943-017-0675-y.
10
Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.不完全射频消融通过激活β-连环蛋白信号通路增强肝癌细胞HCCLM3残余癌的侵袭性和转移能力。
PLoS One. 2014 Dec 26;9(12):e115949. doi: 10.1371/journal.pone.0115949. eCollection 2014.

引用本文的文献

1
Peptide Drug: Design and Clinical Applications.肽类药物：设计与临床应用
MedComm (2020). 2025 Jul 25;6(8):e70287. doi: 10.1002/mco2.70287. eCollection 2025 Aug.
2
Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma.组蛋白乙酰化调节剂的综合多组学分析确定ASH1L为骨肉瘤的一种新型侵袭性标志物。
Discov Oncol. 2025 Jun 12;16(1):1070. doi: 10.1007/s12672-025-02920-6.
3
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

本文引用的文献

1
PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting v integrin/FAK/Src signaling in oral squamous cell carcinoma cells.PEP06多肽30是一种新型的簇解离剂，可抑制口腔鳞状细胞癌细胞中的v整合素/黏着斑激酶/ Src信号通路。
Acta Pharm Sin B. 2019 Nov;9(6):1163-1173. doi: 10.1016/j.apsb.2019.10.005. Epub 2019 Oct 18.
2
High expression of XRCC5 is associated with metastasis through Wnt signaling pathway and predicts poor prognosis in patients with hepatocellular carcinoma.XRCC5 的高表达通过 Wnt 信号通路与转移相关，并预测肝癌患者的预后不良。
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7835-7847. doi: 10.26355/eurrev_201909_18993.
3
基于肽的药物研发进展：递送平台、治疗药物与疫苗
Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5.
4
Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer.PEP06（TB01）与曲氟尿苷/替匹嘧啶（TAS-102）联合应用于人大肠癌异种移植模型中的抗癌作用。
J Cancer Res Clin Oncol. 2024 Dec 26;151(1):22. doi: 10.1007/s00432-024-05984-z.
5
Development and validation of disulfidptosis-related genes signature for patients with glioma.胶质瘤患者二硫化物相关基因特征的开发与验证
Discov Oncol. 2024 Dec 18;15(1):758. doi: 10.1007/s12672-024-01664-z.
6
TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma.TFCP2L1通过调节肝细胞癌中的NANOG/STAT3信号通路来驱动干性并增强其对索拉非尼治疗的抗性。
Oncogenesis. 2024 Sep 12;13(1):33. doi: 10.1038/s41389-024-00534-1.
7
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression.信号蛋白 Semaphorin 3C（Sema3C）重塑基质微环境以促进肝癌进展。
Signal Transduct Target Ther. 2024 Jul 3;9(1):169. doi: 10.1038/s41392-024-01887-0.
8
Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target.肝细胞癌中的Wnt/β-连环蛋白信号通路：致病作用与治疗靶点
Front Oncol. 2024 Apr 2;14:1367364. doi: 10.3389/fonc.2024.1367364. eCollection 2024.
9
Sulfation of chondroitin and bile acids converges to antagonize Wnt/-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis.硫酸软骨素和胆汁酸的硫酸化作用共同拮抗Wnt/β-连环蛋白信号传导，并抑制APC缺陷诱导的肠道肿瘤发生。
Acta Pharm Sin B. 2024 Mar;14(3):1241-1256. doi: 10.1016/j.apsb.2023.12.006. Epub 2023 Dec 16.
10
Wnt/β-catenin-driven EMT regulation in human cancers.Wnt/β-catenin 驱动的人类癌症中的 EMT 调控。
Cell Mol Life Sci. 2024 Feb 9;81(1):79. doi: 10.1007/s00018-023-05099-7.
Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies.
miRNA 调控的癌症干细胞在人类恶性肿瘤发病机制中的作用。
Cells. 2019 Aug 5;8(8):840. doi: 10.3390/cells8080840.
4
Cancer stem cell (CSC) resistance drivers.癌症干细胞（CSC）耐药性驱动因素。
Life Sci. 2019 Oct 1;234:116781. doi: 10.1016/j.lfs.2019.116781. Epub 2019 Aug 17.
5
Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target.球体形成培养富集肝癌干细胞并揭示硬脂酰辅酶 A 去饱和酶 1 作为潜在的治疗靶点。
BMC Cancer. 2019 Aug 1;19(1):760. doi: 10.1186/s12885-019-5963-z.
6
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.索拉非尼耐药的肝癌：缺氧诱导因子的作用。
Exp Mol Med. 2018 Oct 12;50(10):1-9. doi: 10.1038/s12276-018-0159-1.
7
Epithelial-mesenchymal Transition and Cancer Stem Cells: At the Crossroads of Differentiation and Dedifferentiation.上皮-间质转化与癌症干细胞：分化与去分化的十字路口。
Dev Dyn. 2019 Jan;248(1):10-20. doi: 10.1002/dvdy.24678. Epub 2018 Nov 22.
8
miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro.miR-142-3p在体外减弱乳腺癌干细胞特性并降低放射抗性。
Tumour Biol. 2018 Aug;40(8):1010428318791887. doi: 10.1177/1010428318791887.
9
Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.新型 ADAM-17 抑制剂 ZLDI-8 增强索拉非尼对肝癌细胞的体外和体内化疗效果。
Cell Death Dis. 2018 Jul 3;9(7):743. doi: 10.1038/s41419-018-0804-6.
10
A LC-MS/MS method to monitor the concentration of HYD-PEP06, a RGD-modified Endostar mimetic peptide in rat blood.一种 LC-MS/MS 方法，用于监测大鼠血液中 HYD-PEP06（一种 RGD 修饰的恩度模拟肽）的浓度。
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:296-305. doi: 10.1016/j.jchromb.2018.05.042. Epub 2018 May 29.